2-甲氧基-3-硝基-5-(4,4,5,5-四甲基-[1,3,2] 二噁硼烷-2-基)-吡啶 | 1083168-94-8

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸/亚磺酸
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-甲氧基-3-硝基-5-(4,4,5,5-四甲基-[1,3,2] 二噁硼烷-2-基)-吡啶
• 中文别名: 2-甲氧基-3-硝基-5-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)-吡啶；2-萘胺-3,6,8-三磺酸；2-甲氧基-3-硝基吡啶-5-基硼酸频哪醇酯；2-甲氧基-3-硝基-5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)吡啶；2-甲氧基-3-硝基吡啶-5-硼酸频哪醇酯
• 英文名称: 2-methoxy-3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 1083168-94-8
• 化学式: C₁₂H₁₇BN₂O₅
• 分子量: 280.088
• InChiKey: XWXOPFXUTOQOSM-UHFFFAOYSA-N

物化性质

• 熔点：
  118-119°

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  86.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Methoxy-3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Methoxy-3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine
Ingredient name:
CAS number: 1083168-94-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H17BN2O5
Molecular weight: 280.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基-3-硝基-5-(4,4,5,5-四甲基-[1,3,2] 二噁硼烷-2-基)-吡啶 在 吡啶 、 palladium on activated charcoal 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2,4-二氟-n-[2-甲氧基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3-吡啶]-苯磺酰胺
  参考文献：
  名称：

  发现作为活性和口服活性双重抑制剂PI3K / mTOR的嘧啶并嘧啶酮

  摘要：

  一系列嘧啶嘧啶酮衍生物的鉴定和前导优化被描述为一类新型的有效PI3K / mTOR双重抑制剂，导致31的发现。化合物31在细胞分析中显示出对PI3K和mTOR的高酶活性，对Akt和p70s6k磷酸化的有效抑制作用，以及良好的药代动力学特征。此外，化合物31在PC-3M肿瘤异种移植模型中显示出体内功效。

  DOI：

  10.1021/acsmedchemlett.8b00002
• 作为产物：
  描述：

  5-溴-2-甲氧基-3-硝基砒啶 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.0h， 生成 2-甲氧基-3-硝基-5-(4,4,5,5-四甲基-[1,3,2] 二噁硼烷-2-基)-吡啶
  参考文献：
  名称：

  发现作为活性和口服活性双重抑制剂PI3K / mTOR的嘧啶并嘧啶酮

  摘要：

  一系列嘧啶嘧啶酮衍生物的鉴定和前导优化被描述为一类新型的有效PI3K / mTOR双重抑制剂，导致31的发现。化合物31在细胞分析中显示出对PI3K和mTOR的高酶活性，对Akt和p70s6k磷酸化的有效抑制作用，以及良好的药代动力学特征。此外，化合物31在PC-3M肿瘤异种移植模型中显示出体内功效。

  DOI：

  10.1021/acsmedchemlett.8b00002

文献信息

• Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases
  作者：Jordi Bach、Paul Eastwood、Jacob González、Elena Gómez、Juan Antonio Alonso、Silvia Fonquerna、Estrella Lozoya、Adela Orellana、Mónica Maldonado、Elena Calaf、Joan Albertí、Juan Pérez、Ana Andrés、Neus Prats、Cristina Carreño、Elena Calama、Jorge De Alba、Marta Calbet、Montserrat Miralpeix、Isabel Ramis

  DOI：10.1021/acs.jmedchem.9b00533

  日期：2019.10.24

  in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure–activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced

  Janus激酶（JAKs）在调节与哮喘和慢性阻塞性肺疾病有关的炎性细胞因子的表达和功能中起关键作用。本文描述了一系列适合吸入给药的新型嘌呤酮JAK抑制剂的设计，合成和药理学评估。用吡啶酮环代替该系列起始化合物中存在的咪唑并吡啶铰链结合基序可减轻细胞的细胞毒性。由结构生物学研究推动的进一步的系统构效关系（SAR）的努力导致发现了吡啶酮34，一种有效的泛JAK抑制剂，具有良好的选择性，较长的肺保留时间，较低的口服生物利用度，并且在通过吸入途径经脂多糖诱导的气道炎症大鼠模型中被证明具有疗效。
• [EN] FUSED HETEROARYLS AND THEIR USES<br/>[FR] HÉTÉROARYLES CONDENSÉS ET LEURS UTILISATIONS
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2012034526A1

  公开（公告）日：2012-03-22

  Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.

  提供了某些融合的杂环芳基，以及它们的组成物和使用方法。
• FUSED HETEROARYLS AND THEIR USES
  申请人：Su Weiguo

  公开号：US20130190307A1

  公开（公告）日：2013-07-25

  Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.

  提供了某些融合的杂环芳基，以及它们的组合物和使用方法。
• Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2- a ]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors
  作者：Yan-Hua Fan、Wei Li、Dan-Dan Liu、Meng-Xuan Bai、Hong-Rui Song、Yong-Nan Xu、SangKook Lee、Zhi-Peng Zhou、Jian Wang、Huai-Wei Ding

  DOI：10.1016/j.ejmech.2017.07.074

  日期：2017.10

  series compounds containing hydrophilic group in imidazo[1,2-a]pyridine and quinazolin-4(3H)-one were synthesized and their antiproliferative activities against five cancer cell lines, including HCT-116, SK-HEP-1, MDA-MB-231, SNU638 and A549, were evaluated. Compound 1i with most potent antiproliferative activity was selected for further biological evaluation. PI3K kinase assay showed that 1i has selectivity

  磷脂酰肌醇3-激酶（PI3K）是细胞内信号通路的关键调节剂，被认为是癌症治疗方法开发中的有希望的靶标。在不同的PI3K亚型中，编码PI3Kp110α的PIK3CA基因在大多数人类癌症中经常发生突变并过表达。因此，抑制PI3Kα被认为是治疗癌症的有效方法。在这项研究中，合成了在咪唑并[1,2- a ]吡啶和喹唑啉-4（3H）-one中含有亲水基的两个系列化合物，它们对包括HCT-116，SK-HEP-5在内的五种癌细胞系具有抗增殖活性。参照图1，评估了MDA-MB-231，SNU638和A549。化合物1i选择具有最强抗增殖活性的化合物进行进一步的生物学评估。PI3K激酶测定法显示1i对PI3Kα具有选择性，与其他同工型不同。蛋白质印迹分析表明1i在降低磷酸化Akt的水平上比基于咪唑并吡啶的PI3Ka抑制剂HS-173更有效。所有这些结果表明1i是有效的PI3Kα抑制剂，可以被视为开发抗癌药物的潜在候选药物。
• Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors
  作者：Yifan Feng、Weiming Duan、Shu Fan、Hao Zhang、San-Qi Zhang、Minhang Xin

  DOI：10.1016/j.bmc.2019.07.051

  日期：2019.10

  study, a new series of 4-(piperid-3-yl)amino substituted 6-pyridylquinazoline derivatives were synthesized. After biological evaluation, compounds A5 and A8 were identified as potent PI3Kδ inhibitors, with IC50 values of 1.3 and 0.7 nM, respectively, which are equivalent to or better than idelalisib (IC50 = 1.2 nM). Further PI3K isoforms selectivity evaluation showed that compound A5 afforded excellent

  PI3Kδ是开发抗癌药物的引人入胜的目标。在这项研究中，合成了一系列新的4-（哌啶-3-基）氨基取代的6-吡啶基喹唑啉衍生物。经过生物学评估后，化合物A5和A8被确定为有效的PI3Kδ抑制剂，IC 50值分别为1.3和0.7 nM，与艾屈拉西布相当或更好（IC 50  = 1.2 nM）。进一步的PI3K同工型选择性评估表明，化合物A5相对于PI3Kα，PI3Kβ和PI3Kγ具有优异的PI3Kδ选择性。A8表现出优于PI3Kα和PI3Kβ的PI3Kδ/γ选择性。此外，化合物A5和A8选择性地表现出对SU-DHL-6的体外抗增殖，IC 50值为0.16和0.12μM。Western印迹分析表明，A8可以减弱AKT S473的磷酸化。分子对接研究表明，A8与PI3Kδ形成了三个关键的H键作用，这可能解释了其对PI3Kδ的有效抑制作用。这些发现表明4-（哌啶-3-基）氨基取代的6-吡啶基喹唑啉衍